期刊文献+

规范库欣病的诊疗以提高其诊治水平

原文传递
导出
摘要 库欣病(Cushing’s Disease,CD)由Harvey Cushing于1932年首次描述,是由垂体促肾上腺皮质激素(ACTH)腺瘤引起的库欣综合征,临床表现为满月脸、水牛背、多血症、皮肤紫纹、高血压、糖尿病及骨质疏松等。库欣病约占垂体腺瘤的10%,
出处 《中华医学杂志》 CAS CSCD 北大核心 2016年第11期833-834,共2页 National Medical Journal of China
  • 相关文献

参考文献12

  • 1Plotz CM, Knowlton AI, Ragan C. The natural history of cushing's syndrome[J]. Am J Med,1952,13(5) :597-614.
  • 2Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of cushing' s syndrome : a population-based study [ J ]. J Clin Endocrinol Metab, 2001,86 ( 1 ) : 117-123.
  • 3Dekkers OM, Horvath-Puho E, Jorgensen JO, et al. Multisystem morbidity and mortality in cushing's syndrome:a cohort study[ J ]. J Clin Endocrinol Metab, 2013,98 ( 6 ) : 2277-2284.
  • 4Clayton RN, Raskauskiene D, Reulen RC, et al. Mortality and morbidity in cushing's disease over 50 years in stoke-on-trent, uk: Audit and meta-analysis of literature [ J ]. J Clin Endocrinol Metab ,2011,96 (3) :632-642.
  • 5Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma [ J ]. J Clin Endocrinol Metab,2007,92(3 ) :976-981.
  • 6冯铭,姚勇,邓侃,幸兵,连伟,李桂林,魏俊吉,窦万臣,包新杰,刘小海,代从新,高俊,王裕,马文斌,杨义,钟定荣,王任直.经蝶窦入路垂体腺瘤切除术中肿瘤假包膜的意义[J].中华医学杂志,2013,93(35):2813-2815. 被引量:8
  • 7冯铭,王任直.要加强垂体腺瘤治疗过程中残余垂体功能的保护[J].中华医学杂志,2012,92(39):2737-2738. 被引量:2
  • 8Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent cushing's syndrome: a consensus statement [ J ]. J Clin Endocrinol Metab, 2008,93 ( 7 ) : 2454- 2462.
  • 9Valassi E, Biller BM, Swearingen B, et al. Delayed remission after transsphenoidal surgery in patients with cushing's disease [J]. J Clin Endocrinol Metab,2010,95 (2) :601-610.
  • 10Jagannathan J, Smith R, DeVroom HL, et al. Outcome of using the histological pseudocapsule as a surgical capsule in cushing disease [ J ]. J Neurosurg,2009,111 ( 3 ) :531-539.

二级参考文献23

  • 1王任直.目前垂体腺瘤治疗中存在的问题及解决方法[J].中华医学杂志,2006,86(23):1585-1588. 被引量:31
  • 2Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat Rev Cancer,2004,4:285-295.
  • 3Scheithauer BW, Gaffey TA, Lloyd RV, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery, 2006,59 : 341 - 353 ; discussion 341-353.
  • 4Jeffcoate WJ, Pound N, Sturrock ND, et al. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol, 1996,45: 299-303.
  • 5Molitch ME, Russell EJ. The pituitary " incidentaloma". Ann Intern Med, 1990,112:925-931.
  • 6Molitch ME. Pituitary tumors : Cabergoline versus bromocriptine : a meta-analysis? Nat Rev Endocrinol,2011,7 :254-255.
  • 7Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev,2006 ,27 :485-534.
  • 8Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol, 2011,7:267-278.
  • 9Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide lar (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol , 2007,66 : 859-868.
  • 10Bevan JS. Clinical review : the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab,2005,90: 1856-1863.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部